当前位置: X-MOL 学术Neoplasma › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Metabolomic profiling of blood plasma of patients with lung cancer and malignant tumors with metastasis in the lungs showed similar features and promising statistical discrimination against controls.
Neoplasma ( IF 2.0 ) Pub Date : 2021-04-28 , DOI: 10.4149/neo_2021_210103n3
Miroslava Sarlinova 1 , Eva Baranovicova 1 , Michaela Skalicanova 2 , Anton Dzian 2 , Martin Petras 1 , Jan Lehotsky 3 , Dagmar Kalenska 4 , Peter Racay 3 , Tatiana Matakova 3 , Erika Halasova 1, 5
Affiliation  

Targeting metabolomic pathways is a promising strategy for cancer treatment. Alterations in the metabolomic state have also an epigenetic impact making the metabolomic studies even more interesting. We explored metabolomic changes in blood plasma of patients with primary and secondary lung cancer and tried to explore their origin. We also applied a discrimination algorithm on the data. In the study, blood samples from 132 patients with primary lung cancer, 47 with secondary lung cancer, and 77 subjectively healthy subjects without any cancer history were used. The samples were measured by NMR spectroscopy. PCA and PLSDA analyzes did not distinguish between patients with primary and secondary lung tumors. Accordingly, no significantly changed levels of plasmatic metabolites were found between these groups. When comparing with healthy controls, significantly increased glucose, citrate, acetate, 3-hydroxybutyrate, and creatinine balanced with decreased pyruvate, lactate, alanine, tyrosine, and tryptophan were found as a common feature of both groups. Metabolomic analysis of blood plasma showed considerable proximity of patients with primary and secondary lung cancer. The changes observed can be partially explained as cancer-derived and also as changes showing ischemic nature. Random Forrest discrimination based on the relative concentration of metabolites in blood plasma performed very promising with AUC of 0.95 against controls; however noticeable parts of differencing metabolites are overlapping with those observed after ischemic injury in other studies.

中文翻译:

肺癌和肺部转移恶性肿瘤患者血浆的代谢组学分析显示出相似的特征,并有希望与对照组进行统计区分。

靶向代谢组学途径是一种很有前景的癌症治疗策略。代谢组学状态的改变也具有表观遗传影响,使代谢组学研究更加有趣。我们探索了原发性和继发性肺癌患者血浆中的代谢组学变化,并试图探索它们的起源。我们还对数据应用了判别算法。在该研究中,使用了来自 132 名原发性肺癌患者、47 名继发性肺癌患者和 77 名没有任何癌症病史的主观健康受试者的血液样本。通过NMR光谱测量样品。PCA 和 PLSDA 分析没有区分原发性和继发性肺肿瘤患者。因此,在这些组之间没有发现血浆代谢物水平的显着变化。与健康对照相比,葡萄糖、柠檬酸盐、醋酸盐、3-羟基丁酸盐和肌酐平衡显着增加,丙酮酸盐、乳酸盐、丙氨酸、酪氨酸和色氨酸减少被发现是两组的共同特征。血浆代谢组学分析显示,原发性和继发性肺癌患者之间相当接近。观察到的变化可以部分解释为癌症衍生的,也可以解释为显示缺血性质的变化。基于血浆中代谢物相对浓度的随机 Forrest 鉴别表现非常有希望,AUC 为 0.95,与对照相比;然而,差异代谢物的显着部分与其他研究中缺血性损伤后观察到的部分重叠。酪氨酸和色氨酸被发现是两组的共同特征。血浆代谢组学分析显示,原发性和继发性肺癌患者之间相当接近。观察到的变化可以部分解释为癌症衍生的,也可以解释为显示缺血性质的变化。基于血浆中代谢物相对浓度的随机 Forrest 鉴别表现非常有希望,AUC 为 0.95,与对照相比;然而,差异代谢物的显着部分与其他研究中缺血性损伤后观察到的部分重叠。酪氨酸和色氨酸被发现是两组的共同特征。血浆代谢组学分析显示,原发性和继发性肺癌患者之间相当接近。观察到的变化可以部分解释为癌症衍生的,也可以解释为显示缺血性质的变化。基于血浆中代谢物相对浓度的随机 Forrest 鉴别表现非常有希望,AUC 为 0.95,与对照相比;然而,差异代谢物的显着部分与其他研究中缺血性损伤后观察到的部分重叠。观察到的变化可以部分解释为癌症衍生的,也可以解释为显示缺血性质的变化。基于血浆中代谢物相对浓度的随机 Forrest 鉴别表现非常有希望,AUC 为 0.95,与对照相比;然而,差异代谢物的显着部分与其他研究中缺血性损伤后观察到的部分重叠。观察到的变化可以部分解释为癌症衍生的,也可以解释为显示缺血性质的变化。基于血浆中代谢物相对浓度的随机 Forrest 鉴别表现非常有希望,AUC 为 0.95,与对照相比;然而,差异代谢物的显着部分与其他研究中缺血性损伤后观察到的部分重叠。
更新日期:2021-04-29
down
wechat
bug